11 results about "Epithelial cell adhesion molecule" patented technology

The present invention generally relates to a medium composition and method for culturing mesenchymal stem cells (MSCs), in which the medium comprises an epithelial cell adhesion molecule (EpCAM) peptide, particularly a truncated EpCAM polypeptide containing the extracellular domain (EpEX). It significantly enhances cell proliferation and multipotency of the MSCs.

A modified cell is provided that expresses (a) a chimeric antigen receptor targeting GPC3 and / or CD19, and (b) a multispecific antigen binding protein, variant or binding fragment thereof that binds to one or more targets, comprising a first antigen binding protein, variant or binding fragment thereof that binds to EpCAM (epithelial cell adhesion molecule), and a second antigen binding protein, variant or binding fragment thereof, which binds to an immune cell marker, wherein the first antigen binding protein, variant or binding fragment thereof, which binds to EpCAM comprises a heavy chain variable region and / or a light chain variable region comprising a sequence as disclosed herein. Also disclosed are methods of generating / generating cells as disclosed herein and methods of treating with cells as disclosed herein.

The disclosure relates to peptide conjugates specific for Epithelial cell adhesion molecule (EpCAM) and the use thereof to detect and treat epithelial cell-derived cancers such as intrahepatic cholangiocarcinoma (ICC), hepatocellular carcinoma (HCC), breast cancer, colon cancer and basal cell carcinoma of the skin. The disclosure also relates to methods to monitor the therapeutic response of treated patients by detecting expression of EpCAM.

The present invention relates to antigen binding proteins specific for epithelial cell adhesion molecules (EpCAM), variants and fragments thereof, as well as multispecific antigen binding proteins that bind to EpCAM and other targets, such as bispecific T cell conjugates (BiTE). The invention also provides compositions comprising the antigen binding proteins, variants and fragments thereof, cells expressing / secreting them, methods of treatment employing the antigen binding proteins, variants and fragments thereof, and other uses thereof. In one embodiment, the cell is an immune cell, e.g., selected from the group consisting of T cells, macrophages, monocytes, and NK cells. In more specific embodiments, the cells are CAR T cells.

The present invention relates to an anti-epithelial cell adhesion molecule (anti-EpCAM) monoclonal antibody and use thereof. In the anti-EpCAM antibody of the present invention, a biopanning technique using an OPAL library having a diversity of 1×1010 was used, and a group of anti-EpCAM therapeutic antibody candidates was selected through an enzyme-linked immunosorbent assay. FACS verification was performed to confirm the binding of anti-EpCAM candidate antibodies, and the binding affinity of the candidate antibodies in tumor tissues was confirmed through IHC. In addition, the affinity of the candidate antibodies was verified through surface plasmon response analysis. For the two types of candidate antibodies verified above, the potential thereof as ADCs was evaluated, and the spheroid formation inhibitory activity of the candidate antibodies was verified to confirm the degree of inhibition of cancer cell proliferation induction. As a result of evaluating the anticancer efficacy of the candidate antibodies in an orthotropic colon cancer mice model, the candidate antibodies exhibited an excellent anticancer effect. Therefore, the antibodies produced in the present invention are likely to be effectively used as antibody therapeutic agents having an anticancer effect.

Abstract A method for detecting a biological marker in a sample, preferably a biological marker on a cancer cell, the method comprising: (i) contacting the sample with at least one DNA aptamer coupled to a first reagent and wherein the aptamer specifically binds to a first biological marker in the sample to form a first complex; (ii) contacting the first complex of (i) with a second binding agent that specifically binds to the first reagent such that a second complex is formed, wherein the second binding agent is coupled to a reporter molecule; (iii) contacting the second complex (ii) with a substrate for the reporter molecule of the at least one second binding agent; and (iv) detecting the substrate reaction by formation of a reaction product thereby detecting the biological marker in the sample. Biological markers include cytokeratin 8 (CK8), cytokeratin 18 (CK18), human epidermal growth factor receptor 2 (HER2) and epithelial cell adhesion molecule (EpCAM). Abstract 41 / 50 FIGURE 40 Frozen section preparation 4 Sample fixation + Wash (10 dips in PBS) DNA aptamer staining DAB Substrate DAB substrate HRP FAM Anti-FITC conjugated with HRP FAM DNA Aptamer conjugated with FAM HRP Frozen section slide / Touch imprint slide / Cytology slide / Direct smear slide Anti-FITC-HRP Wash (10 dips in PBS) DAB Wash (10 dips in PBS) Hematoxylin counter-staining Wash under tap water Cove rs lip DAB brown precipitate at the location of the aptamer B o min 1 min 15 sec 5 min 15 sec 5 min 15 sec 5 min 15 sec 10 sec 1 min 1 min A + Wash (10 dips in PBS) Total time for aptamer-DAB staining: —18 min 4 1 / 5 0 A B 1 0 m i n 1 m i n D A B s u b s t r a t e 1 5 s e c H R P A n t i - F I T C 5 m i n D N A a p t a m e r s t a i n i n g H R P 1 5 s e c 5 m i n 1 5 s e c D N A A p t a m e r c o n j u g a t e d w i t h F A M 5 m i n D A B W a s h ( 1 0 d i p s i n P B S ) F r o z e n s e c t i o n s l i d e / T o u c h i m p r i n t s l i d e / C y t o l o g y s l i d e / D i r e c t s m e a r s l i d e c o u n t e r - s t a i n i n g 1 m i n W a s h u n d e r t a p w a t e r 1 m i n C o v e r s l i p F I G U R E 4 020 25 28 36 33 19 D ec 2 02 5 1 9 D e c 2 0 2 5 A B 1 0 m i n F r o z e n s e c t i o n p r e p a r a t i o n 1 m i n S a m p l e f i x a t i o n D A B 2 0 2 5 2 8 3 6 3 3 s u b s t r a t e 1 5 s e c W a s h ( 1 0 d i p s i n P B S ) H R P A n t i - F I T C 5 m i n D N A a p t a m e r s t a i n i n g H R P 1 5 s e c 5 m i n A n t i - F I T C - H R P T o t a l t i m e f o r 1 5 s e c D N A A p t a m e r W a s h ( 1 0 d i p s i n P B S ) c o n j u g a t e d w i t h F A M 5 m i n D A B s t a i n i n g : ~ 1 8 m i n W a s h ( 1 0 d i p s i n P B S ) F r o z e n s e c t i o n s l i d e / T o u c h i m p r i n t s l i d e / 1 0 s e c H e m a t o x y l i n C y t o l o g y s l i d e / D i r e c t s m e a r s l i d e c o u n t e r - s t a i n i n g 1 m i n W a s h u n d e r t a p w a t e r 1 m i n C o v e r s l i p F I G U R E 4 0

The disclosure relates to multimers of Glypican-3 (GPC3)-, CD44-, and Epithelial cell adhesion molecule (EpCAM)-specific peptides and the use thereof to detect and treat epithelial cell-derived cancers such as hepatocellular carcinoma (HCC), intrahepatic cholangiocarcinoma (ICC), breast cancer, colon cancer, gastric cancer, ovarian cancer, cervical cancer, and basal cell carcinoma of the skin. The disclosure also relates to methods to monitor the therapeutic response of treated patients using the peptide multimers.

The application discloses a tumor marker for colorectal cancer diagnosis and a nucleic acid aptamer-based detection method, relates to a nucleic acid aptamer sequence for specifically recognizing epithelial cell adhesion molecule (EpCAM) and prion protein (PRNP), EpCAM and PRNP proteins as colorectal cancer diagnosis markers and a method for detecting expression levels in exosomes. The nucleic acid aptamer sequence is obtained by screening a cell-SELEX (systematic evolution of ligands by exponential enrichment) technology with colorectal cancer cells as targets, can be chemically synthesized in vitro, is stable in structure, easy to modify and replace, low in cost and high in reproducibility; and the target protein is highly enriched in exosomes derived from colorectal cancer tumor cells and can be used as a colorectal cancer diagnosis marker. The nucleic acid aptamer obtained by the application can be applied to imaging of human colorectal cancer related malignant tumor cells and derived exosomes, preparation of coupled drugs, clinical diagnosis and development of related kits.

A portable device for early cancer tumor detecting using the advantages of Ep-CAM antigen properties (Epithelial Cell Adhesion Molecule) which adhere to cancer cells and ability to adhere SPIONs. In this invention we calculate the concentration of ferric ions which have to adhere to the cancer cells throw the antigen. We add the antigen mixed with SPIONs to a blood sample and enriches, incubate and then inject it into the device to process it and produce a residual for test. A special Test strip designed for this device consists of two reagents potassium ferrocyanide and potassium thiocyanate. The purpose of using two -reagents test strip is to increase the integrity of the test. If the sample contain cancer tumor cells, then the antigen will stick to this cell with the ferric ions and the device contain a removable filter unit with a micro pore size to prevent tumor cells from passing throw it. If the sample contain cancer cell, the all-ferric ions will stick to it and not passing through the filter. The residual will not contain any ferric ions and the test strip will act nothing. If the sample is free of cancer cell, then the antigen will find nothing to stick with and consequently the ferric ions which will pass through the filter to precipitate in the residual. The test strip will change color according to reaction with ferric ions which is indication of free-cancer sample.

Fibroblast activation protein a (FAP) is a tumor-specific protein and well characterized for its function in tumorigenicity. However, agents against its enzymatic activity or monoclonal antibodies against its cell surface presence are unsuccessful in clinic for uncharacterized reason. In this disclosure, provided is an anti-FAP siRNA and FAP-silencing oligonucleotides comprising anti-FAP siRNAs linked at both ends to aptamers recognizing cancer markers, in particular aptamers recognizing epithelial cell adhesion molecule (EpCAM).

Modified cells are provided that express (a) a chimeric antigen receptor targeting HER2, and (b) a multispecific antigen binding protein, variant or binding fragment thereof that binds to one or more targets, the present invention relates to antigen binding proteins comprising a first antigen binding protein, a variant or a binding fragment thereof, that binds to EpCAM (epithelial cell adhesion molecule) and a second antigen binding protein, a variant or a binding fragment thereof, that binds to an immune cell marker, wherein a first antigen binding protein, a variant or a binding fragment thereof binding to EpCAM comprises a heavy chain variable region and / or a light chain variable region comprising a sequence as disclosed herein. Also disclosed are methods of producing / producing the cells as disclosed herein and methods of treatment employing the cells as disclosed herein.